Keystone Bio to Present at the Sachs 6th Annual Neuroscience Innovation Forum
ST. LOUIS--(BUSINESS WIRE)--Jan 6, 2023--
Keystone Bio, a clinical-stage biotechnology company working to stop inflammatory-based disease at its source, announced today their participation as a keynote speaker at the Sachs 6 th Annual Neuroscience Innovation Forum in San Francisco, CA.
Peter Nara, Chief Scientific Officer of Keystone Bio, will deliver a keynote speech at 11:35 a.m. PST on January 8, 2023 entitled “Virulence Factor-Releasing Porphyromonas gingivalis Driving Neurological Disease: Novel Treatment and Companion Diagnostic.”
To register for or learn more about the Sachs 6 th Annual Neuroscience Innovation Forum, visit sachsforum.com.
About Keystone Bio
Keystone Bio is advancing novel therapeutics and a companion diagnostic to shut down a primary driver of systemic inflammation, the root cause of many neurodegenerative and vascular diseases affecting hundreds of millions of people.
Our lead monoclonal antibody has been shown to eradicate Porphyromonas gingivalis (Pg) at its source, stopping the daily flow of its highly virulent and disease-causing toxins throughout the body. Our team of entrepreneurs and scientists, including the world’s experts in Pg, Alzheimer’s, cardio-metabolic disease, and dentistry is working to stop disease at its source.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230106005047/en/
Megan McGrath or Chelsea Rule
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MISSOURI
INDUSTRY KEYWORD: RESEARCH NEUROLOGY DENTAL CLINICAL TRIALS CARDIOLOGY BIOTECHNOLOGY HEALTH PHARMACEUTICAL SCIENCE
SOURCE: Keystone Bio
Copyright Business Wire 2023.
PUB: 01/06/2023 09:00 AM/DISC: 01/06/2023 09:01 AM